Women
Conditions
Interventions
The group 1 - 20 patients -
Pregabalin + Placebo received pregabalin 150 mg orally 30 minutes before the anesthetic procedure and 12 hours after this dose and during the surgical procedure they used s
Drug
Sponsors
Instituto do Câncer do Ceará
Instituto do Câncer do Ceará
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: women over eighteen years of age; indicated the mastectomy with axillary lymphadenectomy; state physical classification of the American Society of Anesthesiologist (ASA) I and II; with the signed free informed consent form; no history of allergy to pregabalin or magnesium.
Exclusion criteria
Exclusion criteria: patients with previous history of liver or kidney disease or any other pathology that contraindicated the use of pregabalin or magnesium; who had used opioids 48 hours before surgery. patient who would perform breast reconstruction at the same surgical time. patients using calcium channel blockers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| expected outcome 1: better analgesia in the magnesium + pregabalin sulfate group using the visual analogue scale to quantify the pain, using the mean + standard deviation, adopting a 95% confidence level when comparing the four groupss;endpoint found 1: decreased pain in the magnesium sulphate + pregabalin group, visual analogue scale of 1.45 ± 2.33; significantly better analgesia than the other groups with a variation lower than 0.001 | — |
Secondary
| Measure | Time frame |
|---|---|
| expected secondary outcome 1: longer extubation time in the groups using magnesium sulfate, calculated with the time of anesthesia, using mean ± standard deviation and variation less than 5% when compared to the other groups;secondary outcome found 1: there was no increase in the time of extubation in the groups that used magnesium sulphate when compared with the groups that did not use magnesium sulphate; calculated through the time of anesthesia; using the mean + standard deviation, 117.94 ± 26.44 minutes with a change of 0.613 | — |
Countries
Brazil
Contacts
Public ContactJose Nilson Araujo
Instituto do Câncer do Ceará
Outcome results
None listed